# Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2

> **NCT05736549** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 66 (estimated)

## Conditions studied

- Total Knee Replacement
- Knee Arthroplasty

## Interventions

- **DRUG:** Bupivacaine-Liposomal Bupivacaine
- **DRUG:** Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate

## Key facts

- **NCT ID:** NCT05736549
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-07
- **Primary completion:** 2027-09
- **Final completion:** 2028-03
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736549, "Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05736549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*